Swep Bio, Inc. is looking to raise nearly $5 million through a new private offering, as detailed in its recent SEC filing. This move is significant for the company as it seeks to bolster its financial resources in the competitive biotechnology industry.

Founded in 2026 and incorporated in Delaware, Swep Bio, Inc. is based in Scarsdale, New York. The company focuses on biotechnology, a sector that has seen increasing interest and investment in recent years. The filing indicates that Swep Bio is in the early stages of its business operations, with a revenue range that it has chosen to decline to disclose.

The SEC filing, dated October 29, 2026, outlines that the company is utilizing Rule 506(b), which provides a "safer harbor" for private offerings. The total offering amount is set at $4,999,976, with approximately $2,499,989 already sold. This leaves about $2,499,987 remaining in the offering.

According to the filing, the offering does not include any sales commissions or finders fees, indicating a straightforward approach to raising capital. Additionally, the filing states that no amounts other than ordinary course employment compensation are being paid to officers and directors.

This funding initiative may impact various stakeholders, including the company's current investors and potential new investors. With only one investor already involved, the company is likely targeting accredited investors to complete the offering.

As for what’s next, the filing does not specify any upcoming actions or events related to this offering. However, the interest in the biotechnology sector suggests that Swep Bio, Inc. may continue to attract attention as it progresses with its funding goals.